Eurazeo (FR:RF) has released an update.
Eurazeo, in partnership with Kurma Partners, has invested in PanTera through a €93 million financing round aimed at establishing large-scale production of Actinium-225, a promising cancer-fighting radioisotope. This investment marks Eurazeo’s second Growth Equity investment and reinforces its commitment to healthcare innovation in Europe. PanTera plans to significantly increase production to support 100,000 patients annually by 2029, contributing to European medical sovereignty and access to healthcare.
For further insights into FR:RF stock, check out TipRanks’ Stock Analysis page.
